Angelini releases positive new data on Ontozry in epilepsy

Privately-held Italian drugmaker Angelini Pharma today shared positive findings from post-hoc analyses of the C017 open-label extension (OLE) study.

The results, which are being presented as part of the 35th International Epilepsy Congress 2023 taking place in Dublin (Ireland), demonstrated that adjunctive treatment with Ontozry (cenobamate) provided long-term seizure reduction, including seizure freedom, among certain patients with uncontrolled focal-onset epilepsy.

Ontozry is an anti-seizure medication (ASM) approved in Europe in 2021 as adjunctive treatment of focal-onset seizures with or without secondary generalization in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinal products. It was approved in the USA in 2019, where it is marketed under the Xcopri brand.